Phaseline

Targets › CETP

CETP (Cholesteryl ester transfer protein): drug programs, companies and trials

3 programs from 3 companies in 9 trials: 6 Phase 3, 3 Phase 2; Cardiovascular, Neurology, Metabolic and endocrine; next expected readout Nov 2026.

Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL. Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral…. (UniProt, P11597)

Open in Phaseline: the race on CETP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NewAmsterdam Pharmaobicetrapib
Cholesteryl ester transfer protein inhibitor
CETPPhase 3Atherosclerotic Cardiovascular Disease; Lipidemia; Dyslipidemias; Antioxidant Absorption …Nov 2026
DalCor PharmaceuticalsDalcetrapib
Cholesteryl ester transfer protein inhibitor
CETPPhase 3Acute Coronary SyndromeAug 2027
University of OxfordAnacetrapib
Cholesteryl ester transfer protein inhibitor
CETPPhase 3Atherosclerotic Cardiovascular DiseaseJan 2037

Conditions

Lipidemia (3) Atherosclerotic Cardiovascular Disease (2) Dyslipidemias (1) Antioxidant Absorption (1) Preclinical Alzheimer's Disease (1) Acute Coronary Syndrome (1)

Modalities

small molecule (3)

Companies

University of Oxford (1) NewAmsterdam Pharma (1) DalCor Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.